### 2.2.1 In vitro / physico-chemical data

A literature search was performed to collect available information on physicochemical properties of raltegravir. The obtained information from literature is summarized in the table below, and is used for model building.

| **Parameter**   | **Unit**    | **Raltegravir literature**                                 | **Description**                                 |
| :-------------- | ----------- | ---------------------------------------------------------- | ----------------------------------------------- |
| MW              | g/mol       | 444.4163 ([drugbank.ca](#5-References))                    | Molecular weight                                |
| pKa             |             | 6.67 ([Moss 2012](#5-References))                          | Acid dissociation constant                      |
| Solubility (pH) | mg/L        | Reference pH-dependent table  ([Moss 2013](#5-References)) | Solubility                                      |
| logD (pH 7)     |             | 0.58 ([Moss 2012](#5-References))                          | Partition coefficient between octanol and water |
| fu              |             | 0.17 ([Laufer 2009](#5-References))                        | Fraction unbound                                |
| Km UGT1A1       | µM          | 99 ([Kassahun 2007](#5-References))                        | Michaelis-Menten constant                       |
| Vmax UGT1A1     | nmol/min/mg | 0.89 ([Kassahun 2007](#5-References))                      | Maximum rate of reaction                        |
| Km UGT1A9       | µM          | 296 ([Kassahun 2007](#5-References))                       | Michaelis-Menten constant                       |
| Vmax UGT1A9     | nmol/min/mg | 0.53 ([Kassahun 2007](#5-References))                      | Maximum rate of reaction                        |

### 2.2.2 Clinical data

A literature search was performed to collect available clinical data on Raltegravir in adults. 

The following publications were found in adults for model building and evaluation:

| Publication                       | Study description                                            |
| :-------------------------------- | :----------------------------------------------------------- |
| [Iwamoto 2008](#5-References)  | Single- and multiple-dose escalation study in healthy subjects |
| [Iwamoto 2009](#5-References)  | Effects of ritonavir and efavirenz on safety, tolerability and pharmacokinetics of raltegravir |
| [Markowitz 2006](#5-References) | Monotherapy, followed by a longer term combination therapy of raltegravir versus efavirenz |
| [Kassahun 2007](#5-References) | Pharmacokinetics study in healthy adults                     |
| [Rhee 2014](#5-References)     | Pediatric formulation study in healthy adults                |
| [Wenning 2009](#5-References)  | Effect of rifampin on the pharmacokinetics of raltegravir    |

